Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jodie Crawford"'
Autor:
Nawar Diar Bakerly, Dominy Browning, Isabelle Boucot, Jodie Crawford, Sheila McCorkindale, Norman Stein, John P. New
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 15 (2021)
Aim: The Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD) was a randomised controlled trial evaluating the effectiveness and safety of initiating fluticasone furoate/vilanterol (FF/VI) 100/25 µg versus continuing usual care (
Externí odkaz:
https://doaj.org/article/0e25fbfa22b84f6da3da18c66da22f71
Autor:
Carl Abbott, Robert A. Nathan, William W. Busse, Hironori Sagara, John Oppenheimer, Sarah Chang, Nicola A. Hanania, Jodie Crawford, Louis-Philippe Boulet, Geoffrey Chupp, Emilio Pizzichini, Huib A. M. Kerstjens
Publikováno v:
Airway pharmacology and treatment.
Autor:
Susan Collier, Nawar Diar Bakerly, Jørgen Vestbo, John P. New, Ashley Woodcock, Jodie Crawford, Catherine Harvey, David Leather, Isabelle Boucot
Publikováno v:
Bakerly, N D, Woodcock, A, Collier, S, Leather, D A, New, J P, Crawford, J, Harvey, C, Vestbo, J & Boucot, I 2019, ' Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups ', Respiratory Medicine, vol. 147, pp. 58-65 . https://doi.org/10.1016/j.rmed.2018.12.016
Background: SLS COPD was the first open-label randomised controlled trial demonstrating a reduction in moderate/severe COPD exacerbations with once-daily inhaled fluticasone furoate/vilanterol (FF/VI) in everyday clinical practice. Here we report FF/
Autor:
Jodie Crawford, Isabelle Boucot, John P. New, D. Browning, Nawar Diar Bakerly, Norman Stein, Sheila McCorkindale
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 15 (2021)
Bakerly, N D, Browning, D, Boucot, I, Crawford, J, McCorkindale, S, Stein, N & New, J P 2021, ' The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease ', Therapeutic Advances in Respiratory Disease, vol. 15 . https://doi.org/10.1177/17534666211001013
Therapeutic Advances in Respiratory Disease
Bakerly, N D, Browning, D, Boucot, I, Crawford, J, McCorkindale, S, Stein, N & New, J P 2021, ' The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease ', Therapeutic Advances in Respiratory Disease, vol. 15, pp. 17534666211001013 . https://doi.org/10.1177/17534666211001013
Bakerly, N D, Browning, D, Boucot, I, Crawford, J, McCorkindale, S, Stein, N & New, J P 2021, ' The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease ', Therapeutic Advances in Respiratory Disease, vol. 15 . https://doi.org/10.1177/17534666211001013
Therapeutic Advances in Respiratory Disease
Bakerly, N D, Browning, D, Boucot, I, Crawford, J, McCorkindale, S, Stein, N & New, J P 2021, ' The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease ', Therapeutic Advances in Respiratory Disease, vol. 15, pp. 17534666211001013 . https://doi.org/10.1177/17534666211001013
Aim: The Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD) was a randomised controlled trial evaluating the effectiveness and safety of initiating fluticasone furoate/vilanterol (FF/VI) 100/25 µg versus continuing usual care (
Autor:
Hironori Sagara, Andrew Fowler, Soichiro Hozawa, Hiroyuki Ohbayashi, Yoichi Nakamura, Laurie A Lee, Takanobu Nishi, Jun Tamaoki, Jodie Crawford
In CAPTAIN, a double-blind, parallel-group, Phase IIIA study, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) improved lung function, symptoms and asthma control versus FF/VI in patients with inadequately controlled asthma. Here, we report e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87aceaafeba1c5568850a79904d91236
Autor:
Jørgen, Vestbo, David, Leather, Nawar, Diar Bakerly, John, New, J Martin, Gibson, Sheila, McCorkindale, Susan, Collier, Jodie, Crawford, Lucy, Frith, Catherine, Harvey, Henrik, Svedsater, Ashley, Woodcock, S, Kwok
Publikováno v:
Vestbo, J, Leather, D, Bakerly, N D, New, J, Gibson, M, Mccorkindale, S, Collier, S, Crawford, J, Frith, L, Harvey, C, Svedsater, H & Woodcock, A 2016, ' Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice ', The New England Journal of Medicine, vol. 375, pp. 1253-1260 . https://doi.org/10.1056/NEJMoa1608033
Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials t
Effectiveness versus Efficacy Trials in COPD: How study design influences outcomes and applicability
Autor:
Isabelle Boucot, Emma Hilton, Nawar Diar Bakerly, Ashley Woodcock, Jørgen Vestbo, Jodie Crawford, David Leather, Susan Collier
Publikováno v:
Woodcock, A, Boucot, I, Leather, D, Crawford, J, Collier, S, Diar Bakerly, N, Hilton, E & Vestbo, J 2018, ' Effectiveness versus Efficacy Trials in COPD: How study design influences outcomes and applicability. ', European Respiratory Journal . https://doi.org/10.1183/13993003.01531-2017
Guidelines for chronic obstructive pulmonary disease (COPD) management are based largely on results from double-blind randomised controlled trials (RCTs) of efficacy. These trials have high internal validity and test whether a drug is efficacious, bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ec05cda40efbc9934284d608c392e8
https://pure.manchester.ac.uk/ws/files/62223440/Woodcock_Efficacy_vs_effectiveness_manuscript_REVISION2_CLEAN.docx
https://pure.manchester.ac.uk/ws/files/62223440/Woodcock_Efficacy_vs_effectiveness_manuscript_REVISION2_CLEAN.docx
Autor:
JM Gibson, L Stephens, Susan Collier, Jodie Crawford, N Diar Bakerly, Joanne L Fletcher, John P. New, D. Browning
Publikováno v:
Pharmacotherapies for COPD.
Background Adherence to inhaled therapy is key to effective COPD management; poor adherence is associated with suboptimal outcomes. While adherence may be more accurately measured in traditional double-blind randomised controlled trials (RCTs) than i
Autor:
Changzheng Wang, Sang Haak Lee, Jiangtao Lin, Sally Stone, Jian Kang, Jodie Crawford, Loretta Jacques, Xiangdong Zhou
Publikováno v:
Respiratory Medicine. 109:44-53
SummaryBackgroundThis study investigated the efficacy and safety of the inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) combination fluticasone furoate (FF)/vilanterol (VI) in Asian asthma patients.MethodsA 12-week, double-blind, double
Autor:
Ashley, Woodcock, Isabelle, Boucot, David A, Leather, Jodie, Crawford, Susan, Collier, Nawar Diar, Bakerly, Emma, Hilton, Jørgen, Vestbo
Publikováno v:
The European respiratory journal. 51(2)
Guidelines for chronic obstructive pulmonary disease (COPD) management are based largely on results from double-blind randomised controlled trials (RCTs) of efficacy. These trials have high internal validity and test whether a drug is efficacious, bu